The number of data breaches affecting protected health information increased from 216 in 2010 to 566 in 2024. The number of health care data breaches that compromised protected health information ...

Investigators presented an interim analysis of the phase 3 ENLIGHTED trial of photodynamic therapy in patients with low-grade upper-tract urothelial cancer.

Phase 3 trial results suggest that adjuvant treatment with mitomycin and bacillus Calmette-Guérin (BCG) is as safe and effective as BCG alone for patients with high-risk non-muscle invasive bladder ...

The first trial of adjuvant platinum-based chemotherapy plus paclitaxel in patients with high-risk penile cancer provided some insights.

Only incidence and prevalence rates attributable to keratinocyte cancer, DALYs attributable to BCC would increase by 2050. (HealthDay News) — Older adults have a substantial and increasing ...

PARP inhibitors demonstrate synergy with radiation, so investigators tested the efficacy and safety of olaparib plus radium-223 in patients with mCRPC and bone metastases in a phase 2 trial.

Medical AI tools for clinicians and patients have advantages and disadvantages, including implicit bias in triage and virtual urgent care.

The mean monthly launch price increased from $10,954 to $27,891. The prices charged at the US launch of targeted cancer therapies have increased well above the rate of inflation every year since ...

Protective association seen between GLP-1 receptor agonist use and colon and rectal cancers in adults with obesity and diabetes. (HealthDay News) — For adults with diabetes and obesity, glucagon ...

Data from clinical trials have indicated that PSA is prognostic for outcomes, but little is known about real-world trends.

Rapid reduction of glucocorticoid (GC) doses to 7.5 mg/day or less within 6 months may not worsen renal outcomes or increase relapse in patients with proliferative lupus nephritis (LN), recent study ...

The immunotherapy CAN-2409 plus radiation therapy may fill an unmet treatment need for patients with localized intermediate- to high-risk prostate cancer.